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ABSTRACT 
The ultimate aim of the present study was to develop sustained release (SR) tablets of Donepezil Hydrochloride by employing 
natural polymers (Guar gum and Xanthan gum) as the matrix material in different proportion by wet granulation method. Initially 
drug-excipients compatibility studies were carried out using FTIR and DSC which showed no interaction between drug and 
excipients. Granules of prepared batches were evaluated for bulk density, tapped density, carr’s index, hausner’s ratio, angle of 
repose. Tablets were evaluated for various physicochemical parameters like hardness, thickness, friability, weight variation test, drug 
content and in vitro drug release. All the formulation showed compliance with pharmacopoeial standards. 32 full factorial design was 
applied in which Guar gum (X1) and Xanthan gum (X2) were taken as independent factor and %CDR at 2hr (Y1) and at 12hr (Y2) 
were taken as response. In-vitro drug release study revealed that as the amount of polymers increased, % CDR decreased. Contour 
plots as well as response surface plots were constructed to show the effect of X1 and X2 on %CDR and predicted at the concentration 
of independent variables X1(40mg) and X2(40mg) for maximized response. The kinetic release treatment showed that korsmeyer 
peppas equation has shown of  r2 0.9517 which was close to one indicating that the dissolution profile fits in Korsmeyer-Peppas 
model and the mechanism of drug release from these tablets was by non-fickian diffusion mechanism. The optimized batch was kept 
for stability study at 40 ± 2oC/ 75 ± 5 % RH for a period of 1 month according to ICH guidelines and found to be stable after 1 
month of study. 
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INTRODUCTION
 
Oral route is the oldest and convenient way for the 
administration of therapeutic agents because of low 
amount of therapy and ease of administration leads to 
greater level of patient compliance. Approximately 50% 
of the drug products available in the market are 
administered orally and traditionally, oral drug 
administration has been the major route for drug 
delivery. Sustained release systems include any drug 
delivery system that achieves slow release of drug over 
an extend period of time. Sustained release dosage forms 
have been demonstrated to improve therapeutic 
efficiency by maintenance of a steady drug plasma 
concentration. The oral route of administration for 
sustained release systems has received greater attention 
because of more flexibility in dosage form design. So, 
sustained release dosage form is a dosage form that 
release one or more drugs continuously in a 
predetermined pattern for a fixed period of time, either 
systemically or to a specified target organ. Sustained 
release tablets are commonly taken only once or twice 
daily, compared with counterpart conventional forms 
that may have to take three or four times daily to achieve 
the same therapeutic effect. Sustained release products 
provide an immediate release of drug that promptly 
produces the desired therapeutic effect, followed by 
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gradual release of additional amounts of drug to 
maintain this effect over a predetermined period.
1,2
 
Donepezil hydrochloride (DH) is a second-generation 
cholinesterase inhibitor (ChEI), used for the treatment of 
Alziemer’s disease (AD) having greater specificity for 
the brain acetyl cholinesterase enzyme (AchE). This 
compound characterized by a long plasma half-life (70 
hr) and a bioavailability of 100%. Donepezil 
hydrochloride currently formulated as film-coated 
tablets of 5 mg, 10 mg, 23 mg doses for once a day oral 
administration under trend name ARICEPT®. The 
immediate release of cholinesterase inhibitors results in 
a spike in the patient's blood plasma levels within 2 to 5 
hours after administration of the drug. The most 
common adverse events from ARICEPT cholinomimetic 
effects include nausea, diarrhea, insomnia, vomiting, 
muscle cramps, fatigue, bradycardia, abdominal pain, 
and anorexia, resulting in a reduction of patient 
compliance. These undesirable effects are due to the 
initial spike in blood plasma levels. Therefore an initial 
therapeutic regimen is often recommended wherein 
donepezil is first introduced at low doses for several 
weeks followed by the gradual increase to the 
appropriate active dose for the patient. A sustained 
release formulation may be advantageous in reducing the 
undesirable side effects associated with the rapid 
increase in blood plasma concentration levels 
immediately after administration of the drug. Such 
sustained release formulations could provide a uniform 
and constant rate of release over an extended period of 
time, which may achieve a stable and desired blood level 
of donepezil without the initial spike in drug plasma 
level.
3
 Therefore, the aim of the investigation is to 
develop, optimize and characterize the sustain release 
tablet of Donepezil hydrochloride using natural 
polymers. 
MATERIALS AND METHODS 
Donepezil hydrochloride was obtained as a gift sample 
from West Coast Pharmaceutical Works Ltd. 
Ahmedabad, Gujarat. Guar gum, Xanthan gum and 
Starch were procured as a gift sample from Chemdyes 
Corporation, Rajkot, Gujarat. Lactose was obtained as a 
gift sample from Finar chemicals, Ahmedabad, Gujarat. 
Magnesium stearate and Talc were purchased from S. D. 
Fine Chemicals, Mumbai, India. All other chemicals 
were of analytical reagent grade. 
Drug-Excipients Compatibility Study by FTIR
4 
The Fourier transform infrared spectrum was obtained 
using an FT-IR spectrometer. The Donepezil 
hydrochloride and mixture of drug with other excipients 
were previously ground and mixed thoroughly with 
potassium bromide, an infrared transparent matrix, at 1:1 
(Sample: KBr) ratio, respectively. The KBr discs were 
prepared by compressing the powders at a pressure of 5 
tons for 5 min in a hydraulic press. Forty Scan were 
obtained at a resolution of 4 cm
-1
, from 4000 to 600 cm
-1 
at Aum Research lab. 
3
2
 Full Factorial Design
5,6 
A 3
2
 full factorial design was adopted and the amount of 
polymers, Guar gum (X1) and Xanthan gum (X2), were 
taken as independent variables and cumulative 
percentage drug release at 2 hr (Y1), and 12 hr (Y2) was 
taken as dependent variables as shown in Table 1. The 
factors were studied at three levels (-1, 0, +1) indicating 
low, medium and high, respectively, as represented in 
Table 2. The statistical optimization procedure was 
performed with the help of optimization software like 
Design Expert 11.0.4.0 demo version (Stat‑ Ease Inc.). 
The software performs the multiple regression analysis 
(MRA), analysis of variance (ANOVA) and statistical 
optimization. 
The use of regression analysis in 3
2
 full factorial design 
generates polynomial equations for different models, 
with interacting terms and regression coefficients, useful 
in evaluating the responses. The software generates two 
models, particularly, full model (non‑ significant terms 
included) and reduced model (excluding 
non‑ significant terms). In the full model study, the 
responses were analysed using the quadratic equation 
below: 
Y =b0 + b1X1 + b2X2 + b12X1X2 + b11X1
2 
+ b22X2
2
 
where Y is the response evaluated, b0 is the arithmetic 
mean response of 9 runs and bi is the estimated 
coefficient of Xi. The main effects (X1 and X2) represent 
the average result of changing one factor at a time from 
its low to high value. The interaction term (X1 X2) shows 
how the response changes when two factors are 
simultaneously changed. The polynomial terms (X1
2
 and 
X2
2
) were included to investigate nonlinearity. In the 
reduced model study, the non‑ significant terms in the 
quadratic equation are removed using backward 
regression procedure to generate a reduced model which 
is more important in studying the influence of factors on 
the responses evaluated. The value and sign of 
regression coefficient (bi) indicates the magnitude of 
influence of the particular term on the response. The 
regression coefficients give the average change in a 
response when the particular factor is changed by a unit, 
when all the other terms remain constant. A positive sign 
on the regression coefficient indicates the factor has a 
positive effect on the response and negative sign 
indicates a negative effect. 
The software performs the individual analysis of 
responses and calculates the sum of squares (SS), mean 
square (MS), Fischer’s ratio (F statistics) and P value. 
The F statistics and P value give the significance level of 
each term. The terms with a P value less than 0.05 are 
considered significant at a level of significance α = 0.05.
Table 1: Selection of Independent and Dependent Variables 
Independent variables Dependent variables 
X1 X2 Y1 Y2 
Concentration of Guar gum (mg) Concentration of Xanthan gum (mg) % CDR at 2hr % CDR at 12hr 
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Table 2: Selection of Levels for Independent Variables and Coding of Variable 
 
Levels 
 
Coded value 
Independent variables 
Concentration of Guar gum (mg) 
X1 
Concentration of Xanthan gum (mg) 
X2 
Low -1 40 40 
Intermediate 0 50 50 
High +1 60 60 
 
Table 3: Composition of Factorial Design Batches D1 to D9 
Ingredients (mg) D1 D2 D3 D4 D5 D6 D7 D8 D9 
Donepezil Hydrochlorie 23 23 23 23 23 23 23 23 23 
Guar Gum 40 50 60 40 50 60 40 50 60 
Xanthan gum 40 40 40 50 50 50 60 60 60 
Lactose 139.5 129.5 119.5 129.5 119.5 109.5 119.5 109.5 99.5 
Magnesium Stearate 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Talc 5 5 5 5 5 5 5 5 5 
Total Weight   (mg/tablet) 250 250 250 250 250 250 250 250 250 
 
To select matrix polymer, a comparative study was 
carried out. In preliminary trial batches, different 
concentrations of Guar gum and Xanthan gum were 
screened. Donepezil Hydrochloride and other excipients 
are weighed accurately, transferred in mortar and pestle 
and thoroughly mixed for 15 min. The powder mixture 
was granulated with 10 % w/v starch paste. The wet 
mass was passed through 10# sieve and granules were 
dried at 50°C for 30 min. in hot air oven. The dried 
granules were passed through 20# sieve and lubricated 
with talc and magnesium stearate which was previously 
passed through 80# sieve. Tablets were compressed 
using 8 mm punch on 10 station rotary tablet punching 
machine (Karnavati Engineering). Composition of 
tablets is mentioned in Table 3. Hardness of the tablets 
was maintained between 5.0 to 6.0 Kg/cm
2
 and tablet 
weight at 250 mg.
7
 
Pre Compression Evaluations
8,9 
The evaluation of Pre compression parameters such as 
Bulk density, Tapped density, Carr’s index, Hausner’s 
ratio and Angle of repose of the granules. 
Post Compression Evaluation
 
The prepared tablets were evaluated for physical and 
chemical characteristics. 
Diameter
10
 
Tablets of each batch were selected and measured for 
diameter using vernier caliper. 
Thickness
10
 
The thickness of five randomly selected tablets was 
measured using vernier calipers. The extent to which the 
thickness of each tablet deviated from ± 5% of the 
standard value was determined.
 
Weight Variation
11
 
Uniformity of the weight test as described in the IP/BP 
was followed. Twenty tablets were selected at random 
and average weight was determined. Then individual 
tablets were weighed and the individual weight was 
compared with the average weight. The percentage 
deviation was calculated and checked for weight 
variation. Using this procedure weight variation range of 
all batches of formulations was determined and 
recorded. 
                    
                      
                
 
Hardness
11
 
The hardness of the tablets was determined by diametric 
compression using a Monsanto Hardness tester. A tablet 
hardness of about 5-6 kg/cm
2 
is considered adequate for 
mechanical stability. Determinations were made in 
triplicate. The mean values and standard deviation for 
each batch were calculated. 
Friability
11
 
The friability of tablets was performed in a Roche 
Friabilator. Five tablets were weighed together and then 
placed in the chamber. The friabilator was operated for 
100 revolutions and the tablets were subjected to the 
combined effects of abrasion and shock because the 
plastic chamber carrying the tablets drops them at a 
distance of six inches with every revolution. The tablets 
are then dusted and re-weighed. 
  
               
        
       
Drug Content
4
 
The drug content was carried out by weighing ten tablets 
from each batch and calculated the average weight. 
Then the tablets were triturated to get a fine powder. 
From the resulting triturate, powder was weighed 
accurately which was equivalent to 23 mg of Donepezil 
hydrochloride and dissolved in 100 ml volumetric flask 
containing 100 ml of dissolution media and volume was 
made to 100 ml with solvent. The volumetric flask was 
shaken using sonicator for 1 hr. and after suitable 
dilution with dissolution media, the drug content was 
determined using UV-Visible Spectrophotometer at 229 
nm. 
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In-vitro Drug Release Study
4
 
Release of the prepared tablets was determined using 
U.S.P type II paddle type dissolution rate test apparatus 
(TDT-06P, Electrolab) using 900 ml of 0.1 N HCl 
medium for 120 minutes, then in phosphate buffer pH 
6.8 medium for 12hrs. as dissolution medium. The 
temperature of 37±1ºC was maintained and paddle was 
adjusted at 25 rpm throughout the experiment. 
Withdrawn not less than 5 ml of the dissolution solution 
at 1, 2, 4, 6, 8, 10, 12, 14hr time interval and were 
replaced with 5 ml of fresh dissolution media after each 
withdrawal. Filtered each sample through a membrane 
filter with pore size of not more than 0.45 mm. The 
samples were analyzed after appropriate dilution by UV 
spectrophotometer at λ max 229 nm. 
Statistical Analysis
5,6
 
Statistical Analysis of the 3
2 
full factorial design batches 
was performed by multiple regression analysis using 
Microsoft excel. In this design 2 factors are evaluated, 
each at 3 levels, and experimental trials are performed at 
all 9 possible combinations. To evaluate the contribution 
of each factor with different levels to the response, the 
two-way analysis of variance (ANOVA) was performed 
using the Design Expert 11.0.4.0 (STAT – EASE) trial 
version software. To graphically demonstrate the 
influence of each factor on the response, the response 
surface plots, Normal plot of residual, Two- 
Dimensional counter plot, 3-D graph, and overlay plot 
were generated using the Design Expert 11.0.4.0 (STAT 
– EASE) demo version software. 
Check point Analysis
5,6
 
A checkpoint analysis was performed to confirm the 
role of the derived polynomial equation and contour 
plots in predicting the responses. Values of independent 
variables were taken at 3 points and the theoretical 
values of %CDR at 2hr and %CDR at 12hr were 
calculated by substituting the values in the polynomial 
equation. 
Optimization of Formulation
5,6
 
The computation for optimized formulation was carried 
using software, Design Expert 11.0.4.0 (STAT – 
EASE). The optimized formulation was obtained by 
applying constraints (goals) on dependent (response) 
and independent variables (factors). The models were 
evaluated in terms of statistically significant coefficients 
and R
2
 values. Various feasibility and grid searches 
were conducted to find the optimum parameters. 
Various 3D response surface graphs were provided by 
the Design Expert software. The optimized formulation 
factors were evaluated for various response properties. 
Curve Fitting Analysis
12
 
In order to describe the kinetics of drug release from 
sustained release formulation, various mathematical 
equations have been proposed namely, Zero order, First 
order, Higuchi model and Hixson–Crowell cube root 
law. To authenticate the release model, dissolution data 
can further be analyzed by Korsmeyer Peppas equation. 
The criteria for the selection of most suitable model 
were value of regression coefficient (R
2
) nearer to 1, 
smallest values of Residual sum of squares (SSR) and 
Akaike Information Criteria (AIC). 
Similarity and Dissimilarity Study
4,12 
The similarity factor f2 as defined by FDA and EMEA 
is a logarithmic reciprocal square root transformation of 
one plus the mean squared (the average sum of squares) 
differences of drug percent dissolved between the test 
and reference products: 
 
Where, n is the number of dissolution time points, Rt 
and Tt are the reference and test dissolution values 
(mean of at least 12 dosage units) at time t. 
When the two dissolution profiles are identical, f2 = 50 
* log (100) = 100, and when the dissolution of one 
product (test or reference) is completed before the other 
begins, f2 = 50 * log {(1 + 1/n Σ (100) 2)-0.5 * 100} = -
0.001, which can be rounded to 0. Thus the value of f2 
ranges from 0* to 100. Two dissolution profiles are 
considered ‘similar’ when the f2 value is between 50 
and 100. Thus FDA recognizes the profiles to be similar 
when the two drug profiles differ only by a difference of 
10%. A higher f2 value indicates closeness between the 
two dissolution profiles. 
Difference factor (f1) measures the percent error 
between two curves over all time points. 
 
Where, n is the sampling number, R and T are the % 
dissolved of reference & test products at each time point 
j. The percent error is zero when the test and drug 
reference profiles are identical and increase 
proportionally with the dissimilarity between the two 
dissolution profiles. It is generally accepted that values 
of f1 between 0- 15 do not indicate dissimilarity. 
Stability Study
13
 
The purpose of stability testing is to provide evidence on 
how the quality of a drug substance or drug product 
varies with time under the influence of temperature, 
humidity, and light and to establish a retest for the drug 
substance or a shelf life for the drug product and 
recommended storage conditions.  The storage 
conditions used for accelerated stability studies were 
accelerated condition (40 ºC ± 2°C / 75% ± 5 % RH) 
and Room temperature (30 ºC ± 2ºC / 65 % RH ± 5 %). 
Stability study was carried out for the most satisfactory 
formulations. Tablets of optimized formulation were 
striped packed and kept in humidity chamber for 1 
month on above mention temperature. 
RESULTS AND DISCUSSION 
Drug Excipients Compatibility Study by FT-IR 
The FTIR spectra of pure drug and mixture of drug with 
excipient are shown in Figure 1. From this it is clear that 
the characteristic peaks at 1696.21 (C=O stretching), 
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1602.74 (C=C stretching), 1312.17 (C-N stretching) 
748.14 (aromatic –CH Stretching) cm-1 are present in 
both the pure drug and mixture of drug with excipient, 
without any change in their positions, indicating no 
chemical interaction between drug and excipients.
 
 
Figure 1: FT-IR Spectra of Donepezil Hydrochloride and all Excipient 
 
Pre-compression Evaluation of Powder Blend of 
Batches D1 to D9 
Granules prepared for compression of matrix tablets 
were evaluated for their flow properties, the results were 
shown in Table 4. Bulk density ranged from 0.572 ± 
0.041 to 0.632 ± 0.025 gm/ml, tapped density ranged 
from 0.667 ± 0.049 to 0.739 ± 0.038 gm/ml, Carr’s 
index ranged from 12.50 ± 1.25% to 14.74 ± 1.88%, 
Hausner’s ratio ranged from 1.14 ± 0.17 to 1.17 ± 0.69 
whereas Angle of repose ranged from 24.15 ± 2.27 to 
27.75 ± 2.28. All these results indicated that, the powder 
blends possess excellent to good flowability and 
compressibility properties. 
 
Table 4: Pre-Compression Evaluations of Design Batches D1 to D9   
Batch 
Code 
Bulk density 
(gm/ml) 
Tapped density 
(gm/ml) 
Compressibility 
index 
(%) 
Hausner’s ratio 
Angle of repose 
(Ө) 
D1 0.588 ± 0.031 0.689 ± 0.024 14.70 ± 1.30 1.17 ± 0.69 27.75 ± 2.28 
D2 0.579 ± 0.039 0.669 ± 0.031 13.45 ± 1.24 1.15 ± 0.21 25.46 ± 1.43 
D3 0.584 ± 0.032 0.675 ± 0.028 13.48 ± 1.21 1.15 ± 0.25 26.56 ± 1.31 
D4 0.630 ± 0.044 0.739 ± 0.038 14.74 ± 1.88 1.17 ± 0.27 24.15 ± 2.27 
D5 0.575 ± 0.053 0.667 ± 0.049 13.79 ± 1.27 1.16 ± 0.05 27.34 ± 1.25 
D6 0.625 ± 0.045 0.714 ± 0.042 12.50± 1.25 1.14 ± 0.17 25.32 ± 1.25 
D7 0.594 ± 0.032 0.691 ± 0.028 14.03 ± 1.20 1.16 ± 0.21 25.30 ± 2.15 
D8 0.632 ± 0.025 0.726 ± 0.021 12.94 ± 1.26 1.14 ± 0.57 24.30 ± 1.15 
D9 0.572 ± 0.041 0.668 ± 0.036 14.43 ± 1.29 1.16 ± 0.35 25.82 ± 2.52 
All values are expressed as mean ± standard deviation, n=3 
 
Post Compression Evaluation of Batches D1 to D9 
The tablets from all the batches were evaluated for 
various physical parameters before proceeding further. 
Table 5 includes the values (mean ± SD) of weight 
variation, hardness, thickness, friability and % drug 
content of batches prepared using different combinations 
of functional excipients. Weight of the tablets in all the 9 
batches varied between 249.26 ± 0.47 to 251.24 ± 
0.32mg. All the formulated (D1 to D9) tablets passed 
weight variation test as the % weight variation was 
within the pharmacopoeial limits of ±5% of the weight. 
Diameter of all tablets was in the ranged from 
7.97±0.002 mm to 7.99±0.004 mm. Thickness of all 
tablets was in the range between 3.20 ± 0.037 mm to 
3.62 ± 0.028mm. Hardness of tablets was in range 
between 5.11 ± 0.023 to 5.91± 0.031 kg/cm
2
. Friability 
was in range between 0.30 ± 0.04 to 0.58± 0.45%. 
Friability values were less than 1 % in all cases which 
shows good mechanical strength at the time of handling 
and transports. Drug content of all tablets was found in 
the range between 98.65 ± 2.20 to 99.82 ± 1.32%. Thus, 
all the physical parameters of the compressed tablets 
complies the standards. 
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Table 5: Post-Compression Evaluation Parameters of Full Factorial Design Batches 
Batch 
Code 
Weight 
variation 
(n=20) 
 
Diameter 
(n=5) 
Thickness 
(mm) 
(n=5) 
Hardness 
(kg/cm
2
) 
(n=5) 
% Friability 
(n=5) 
% Drug 
Content 
(n=10) 
D1 Pass 7.99 ± 0.002 3.28 ± 0.015 5.91± 0.031 0.46 ± 0.17 99.21 ± 1.30 
D2 Pass 7.98 ± 0.003 3.62 ± 0.028 5.49 ± 0.014 0.47 ± 0.32 98.66 ± 1.87 
D3 Pass 7.99 ± 0.004 3.37 ± 0.035 5.11 ± 0.023 0.58 ± 0.45 99.07 ± 0.71 
D4 Pass 7.99 ± 0.003 3.42 ± 0.032 5.68 ± 0.091 0.30 ± 0.45 99.52 ± 1.42 
D5 Pass 7.97 ± 0.002 3.37 ± 0.054 5.75 ± 0.072 0.50 ± 0.25 99.33 ± 1.52 
D6 Pass 7.98 ± 0.002 3.28 ± 0.075 5.82 ± 0.055 0.58 ± 0.03 98.65 ± 2.20 
D7 Pass 7.98 ± 0.004 3.45 ± 0.047 5.70 ± 0.058 0.45 ± 0.15 99.05 ± 1.15 
D8 Pass 7.99 ± 0.004 3.60 ± 0.041 5.54 ± 0.039 0.30 ± 0.04 99.82 ± 1.32 
D9 Pass 7.99 ± 0.001 3.20 ± 0.037 5.41 ± 0.015 0.52 ± 0.05 99.1 ± 0.32 
All values are expressed as mean ± standard deviation 
 
In vitro Drug Release Study of Batches D1 to D9  
Batch D1 to D9 were developed using different 
concentration of Guar Gum (40, 50 & 60 mg) and 
Xanthan gum (40, 50 & 60 mg). Results of % CDR 
study are shown in Figure 2. From the figure, it was 
observed that as the concentration of polymers Guar 
gum and Xanthan gum increases, amount of drug release 
decreases. Results exhibited that batch D1 containing 
40mg of guar gum and 40mg of xanthan gum have 
shown better drug release (99.74%) compared to other 
batches and it was similar to marketed product ALZIL 
SR23. Further this batch fulfills drug release as per the 
requirement at 2hr and 12hr. So, batch D1 was 
considered as optimized batch among all formulated 
batches on the basis of drug release. 
 
 
Figure 2: Cumulative % Drug Release Study of D1 to D9 Batches 
Statistical Analysis 
Preliminary investigations of the process parameters 
revealed that factors concentration of Guar gum (X1) and 
concentration of Xanthan gum (X2) highly influenced 
the rate of in vitro dissolution and, hence, were used for 
further systematic studies.  
Effect of Polymers on %CDR at 2hr 
Mathematical relationships generated for the studied 
response variables concentration of Guar gum (X1) & 
concentration of Xanthan gum (X2) for %CDR at 2hr 
(Y1) is as follows: 
Y1 = 30.07 – 2.24X1 – 4.54X2 – 3.09X1X2 - 0.2567X1
2 
+ 
3.85X2
2
 ,  R
2
 = 0.9884 
The high values of correlation coefficients for %CDR at 
2hr indicate a good fit. The polynomial equations can be 
used to draw conclusions after considering the 
magnitude of coefficient and the mathematical sign it 
carries, i.e positive or negative. Multiple linear 
regression analysis revealed that coefficient b1 and b2 is 
negative. This indicates that as the concentration of 
polymer decreases, %CDR increases. Low levels of X1
 
and of X2 were found to be favorable conditions for 
obtaining better dissolution. Table 6 shows the results of 
analysis of variance (ANOVA), which was performed to 
identify insignificant factors. The coefficients b1, b2, b12
 
and b2
2
 were found to be significant at P is less than 0.05 
and thus, were retained in the reduced model equation. 
Y1 = 30.07 – 2.24X1 – 4.54X2 – 3.09 X1X2 + 3.85
 
X2
2
 , 
R
2
 = 0.9878
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Table 6: ANOVA Response Surface Quadratic Model for %CDR at 2hr 
Source SS Df MS F Value p-value prob > F 
Model 221.77 5 44.35 51.30 0.0042 
X1 30.02 1 30.02 34.72 0.0098 
X2 123.67 1 123.67 143.04 0.0013 
X1X2 38.25 1 38.25 44.24 0.0069 
X1
2
 0.1318 1 0.1318 0.1524 0.7223 
X2
2
 29.70 1 29.70 34.35 0.0099 
Residual 2.59 3 0.8646 - - 
Cor Total 224.36 8 - - - 
 
The 2D and 3D response surface for responses Y1 was also drawn to study the effect of variables on response and it 
was shown in Figure 3. 
 
 
Figure 3: 2D and 3D Curve Concentration of Guar gum (X1) & Xanthan gum (X2) for %CDR at 2hr (Y1) 
Effect of Polymers on %CDR at 12hr 
Mathematical relationships generated for the studied 
response variables concentration of Guar gum (X1) & 
concentration of Xanthan gum (X2) for %CDR at 12hr 
(Y2) is as follows: 
Y2 = 74.83 – 5.23X1 – 4.94X2 – 0.3075X1X2 + 2.96X1
2 
+ 
4.55X2
2
 ,  R
2
 = 0.9734 
The high values of correlation coefficients for %CDR at 
2hr indicate a good fit. The polynomial equations can be 
used to draw conclusions after considering the 
magnitude of coefficient and the mathematical sign it 
carries, i.e positive or negative. Multiple linear 
regression analysis revealed that coefficient b1 and b2 is 
negative. This indicates that as the concentration of 
polymer decreases, %CDR increases. Low levels of X1 
and of X2 were found to be favorable conditions for 
obtaining better dissolution. Table 7 shows the results of 
analysis of variance (ANOVA), which was performed to 
identify insignificant factors. The coefficients b1, b2 and 
b2
2
 were found to be significant at P is less than 0.05 and 
thus, were retained in the reduced model equation. 
Y2 = 74.83 – 5.23X1 – 4.94X2 + 4.55X2
2
 ,  R
2
 = 0.9262
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Table 7: ANOVA Response Surface Quadratic Model for %CDR at 12hr 
Source SS Df MS F Value p-value prob > F 
Model 370.14 5 74.03 21.98 0.0144 
X1 164.12 1 164.12 48.74 0.0060 
X2 146.62 1 146.62 43.54 0.0071 
X1X2 0.3782 1 0.3782 0.1123 0.7596 
X1
2
 17.56 1 17.56 5.22 0.1066 
X2
2
 41.47 1 41.47 12.31 0.0392 
Residual 10.10 3 3.37 - - 
Cor Total 380.25 8 - - - 
 
The 2D and 3D response surface for responses Y2 was also drawn to study the effect of variables on response and it 
was shown in Figure 4. 
 
 
Figure 4: 2D and 3D Curve Concentration of Guar gum (X1) & Xanthan gum (X2) for %CDR at 12hr (Y2) 
 
Check Point Analysis 
Three check point batches were prepared and evaluated 
for %CDR at 2hr and %CDR at 12hr as shown in table 
8. When measured % CDR values were compared with 
predicted % CDR, the differences were found to be not 
significant. Thus, it can be concluded that the obtained 
mathematical equation is valid for predicted values.
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Table 8: Checkpoint Batches with Predicted and Measured Value of %CDR at 2hr and at 12hr 
Batch Code X1 X2 
%CDR at 2hr  
(Y1) 
%CDR at 12hr 
(Y2) 
Measured Predicted Measured Predicted 
D10 0 0.5 28.31 28.76 73.48 73.53 
D11 0.5 1 26.50 26.65 72.36 72.41 
D12 1 0.5 24.51 24.42 71.02 71.07 
 
Optimization of Formulation 
The overlay plot of responses generates an optimized 
area as per desired criteria (Figure 5). This was the most 
important part of the response surface methodology. The 
formulation of the drug which released the drug in 
controlled and complete manner was selected for 
optimum formulation. After studying the effect of the 
independent variables on the responses, the levels of 
these variables that give the optimum response were 
determined. The optimum formulation was selected 
based on the criteria of attaining complete and 
controlled drug release. Batch D1 having 40 mg of Guar 
gum and 40 mg of Xanthan gum fulfilled maximum 
requisites of an optimum formulation because of better 
regulation of release rate. The said formulation released 
37.35% of drug in 2 hr. and 92.84% in 12 hr., however, 
the drug completely got released i.e. 99.74% in 14 
hours, which were in close agreement with the 
theoretical values. 
 
 
Figure 5: Overlay Plot of Batch D1 
Drug Release Kinetic Study 
In order to examine the kinetic of drug release from 
prepared sustained release tablets, the dissolution data of 
optimized formulation D1 was fitted into different 
kinetic models i.e. Zero order, First order, Higuchi 
model, Hixson- Crowell and Korsemeyer-Peppas model 
(Figure 6 to 10). The criteria for the selection of most 
suitable model were value of regression coefficient (R
2
) 
nearer to 1, smallest values of Residual sum of squares 
(SSR) and Akaike Information Criteria (AIC). Table 9 
shows the data obtained. The optimized formulation 
fitted well into Korsemeyer-Peppas, it was confirming 
the desired release profile. The calculated R
2
 value for 
Korsemeyer-Peppas was 0.9517. According to 
Korsemeyer-Peppas equation, the release exponent “n” 
value is between 0.45 < n <0.89, which indicates that 
drug release is non-fickian diffusion type and states that 
release followed the diffusion controlled mechanism. 
 
Table 9: Fitting of Release Profile of Optimized Formulation to Kinetic Models 
Batch Model 
Parameters Used 
R
2
 R K SSR AIC 
 Zero-order 0.7592 0.9743 8.102 2858.1321 129.326 
 First-order 0.8785 0.9532 0.171 1442.0205 118.380 
D1 Higuchi 0.9317 0.9770 25.584 574.4741 105.627 
 Korsemeyer –Peppas 0.9517 0.9772 
25.378 
n=0.504 
573.2614 103.621 
 Hixson Crowell 0.8755 0.9639 0.045 1477.8248 118.773 
Design-Expert® Software
Factor Coding: Actual
Overlay Plot
%CDR at 2hr
%CDR at 12hr
Design Points
X1 = A: Conc of Guar gum
X2 = B: Conc of Xanthan gum
28.6676 38.6676 48.6676 58.6676 68.6676
31.2159
41.2159
51.2159
61.2159
71.2159
Overlay Plot
A: Conc of Guar gum (mg)
B
: C
o
n
c 
o
f 
X
an
th
an
 g
u
m
 (
m
g
)
%CDR at 2hr: 40
%CDR at 2hr: 40
%CDR at 12hr: 95
%CDR at 2hr:   37.3534 
%CDR at 12hr:   92.8434 
X1  40 
X2  40 
 Patel et al                                                                                                               Journal of Drug Delivery & Therapeutics. 2018; 8(3):64-74            
ISSN: 2250-1177                                                                              [73]                                                                              CODEN (USA): JDDTAO 
 
Figure 6: Zero-order Release Kinetic Model 
 
 
Figure 7: First-order Kinetic Model 
 
 
Figure 8: Krosemeyer-Peppas Kinetic Model 
 
Figure 9: Higuchi Kinetic Model 
 
 
Figure 10: Hixon Crowell Kinetic Model 
Similarity and Dissimilarity Study 
Similarity factor (F2) and dissimilarity factor (F1) were 
calculated for optimized batch D1 and values were 
found to be 76.80 and 1.73 respectively. F2 value was 
within 50 to 100 and F1 value was within 0 to 15. This 
indicates that sustained release matrix tablets prepared 
using guar gum and xanthan gum (Batch D1) is similar 
to the marketed tablet formulation (ALZIL SR-23). 
 
Figure 11: Comparison % CDR of Optimized Batch 
with Marketed Product 
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Comparison %CDR of marketed product and optimized 
formulation was presented in Figure 11. 
Stability Study 
Stability study of sustained release matrix tablet of 
Donepezil hydrochloride (batch D1) was carried out for 
1 month at specified condition. All data are mentioned 
in table 10. The stability studies of the optimized 
formulation (batch D1) shown no significant changes in 
the % drug content and % drug release at 14 hr. when 
stored at 40 ± 2
o
C/ 75 ± 5 % RH. 
 
Table 10: Stability Study of Optimized Formulation (D1) carried out at 40 ± 2
o
C/ 75 ± 5 % RH 
No. of Months 
%Drug Content 
(n=3) 
% Drug release at 14 hr. 
(n=3) 
0 99.21 ± 1.30 99.74 ± 3.24 
1 99.36 ± 1.47 99.49 ± 3.72 
All values are expressed as mean ± standard deviation, n=3 
CONCLUSION 
The matrix type of tablets is potential to be an effective 
sustained release drug delivery system over a prolong 
period of time. The type and level of polymer used are 
important factors that can affect the drug release and 
also the physicochemical properties of this sustained 
release matrix tablets. 3
2
 full factorial design was 
applied to achieve controlled drug release up to 14 hr. 
Among all the developed formulations, D1 formulation 
which contained the mixture of two polymers Guar gum 
and Xanthan gum sustained drug release for 14 hr. when 
compared with other formulations and also similar as 
marketed formulation. So, D1 was selected as the best 
formulation. The drug release kinetics follows 
Korsemeyer-peppas and the mechanism was found to be 
non Fickian and shows continuous and uniform drug 
release for extended period of time. The stability studies 
were carried out according to ICH guideline which 
indicates that the selected formulation was stable. From 
the economical point of view, it may be beneficial for 
the local pharmaceutical firms to adopt such simple 
technologies for the preparation of sustained release 
product. 
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